Besser als FLAMEL: BioSANTE - 500 Beiträge pro Seite

[Neoe]

Keinem, der sich an der Diskussion im Nanoboard beteiligt, wird der kometenhafte Kursanstieg von Flamel entgangen sein. Obwohl Flamel sicher ein gutes Unternehmen ist, kann man bei 35$ pro Aktie derzeit nur noch den Kopf schütteln.


Die (meiner Meinung nach sogar weit) bessere Alternative:



BioSANTE Pharma

Ähnlich der Technik von Flamel, hat BioSANTE ebenfalls ein DeliveryTechnology:



Standbein Nummer 1
Calcium Phosphate Nanoparticles (CAP)

BioSante`s CAP nanoparticles are vehicles for delivering drugs and vaccines and enhancing the effects of vaccines. The key component, calcium phosphate, is on the FDA`s GRAS (Generally Regarded as Safe) list. BioSante`s CAP nanoparticles also have successfully passed the first stage of toxicity studies for administration orally, into muscles, under the skin and into the lungs by inhalation.


1.Vaccine Adjuvants

Most vaccines require the use of adjuvants to generate adequate protective immunity to prevent or treat diseases. As a result, most vaccines are combined with an adjuvant that enhances the ability of an injected vaccine to stimulate an immune response and thus protect the recipient by preventing or treating diseases. Currently, there is only one FDA-approved adjuvant for human use available, aluminum hydroxide or alum.

BioSante`s vaccine adjuvant (BioVant™) when combined with vaccines has been shown in animal studies, to elicit a higher immune response than non-adjuvanted vaccines and an immune response of the same magnitude as alum-formulated vaccines, at up to 100 times lower concentration of adjuvant.

BioSante has conducted animal studies to demonstrate the safety and efficacy of BioVant™ using various viruses and bacteria including flu, genital herpes, HIV, Epstein Barr and TB. Animal studies demonstrate that CAP elicits positive immune response to vaccines using either DNA-based or traditional protein antigen formulations.



2.Protein Delivery (Insulin)

BioSante has developed what it believes to be formulations for the oral delivery (BioOral™) of proteins, for example, insulin. These oral formulations are in pre-clinical testing. BioSante also has developed what it believes to be improved formulations for delivering proteins, for example, insulin to the lungs (BioAir™), more efficiently and less expensively than traditional methods. Today, insulin is given by frequent, inconvenient and often painful injections. Recent human clinical research indicates insulin delivered into the lungs can achieve the same result as injections. Pre-clinical trials of both BioOral and BioAir indicate sustained delivery of insulin with sustained control of glucose levels. Similar formulations may be used for the delivery of other proteins, for example, human growth hormone orally or to the lungs.

BioSante has completed pre-clinical tests showing both BioOral™ and BioAir™ extended the hypoglycemic effect of insulin when administered orally, sucutaneously and into the lungs. Study result have been and continue to be presented at various medical meetings.



3.Milk Protein Isolation

BioSante Pharmaceuticals, Inc. has been recently issued a U.S. patent for the advanced method of selectively isolating biologically active therapeutic proteins from transgenic milk in a casein-free supernatant.

Obtaining commercially viable yields of recombinant target protein from the milk of transgenic livestock remains a challenging task since milk is a complex, multiphasic (fat, casein, micelles, whey) colloidal suspension. We believe our patented process effectively addresses these well-known challenges and offers significant efficiency and economy compared to the currently employed methods.

BioSante`s objective is to license this technology on a royalty basis to companies interested in the production of therapeutic proteins in the milk of transgenic animals.

Known Limitations of Current Methods of Extracting Therapeutic Proteins:

Expensive, labor intensive and produce relatively low yields
Complexity of milk composition; cream-whey proteins-casein micelles
Casein constitutes 70 to 80 percent of the total milk protein and are insoluble
Caseins naturally form clusters and trap therapeutic proteins inside
The Advantages of the BioSante Transgenic Protein Delivery Process:

Dissolves the casein clusters, freeing the therapeutic proteins
Removes casein from the therapeutic protein, while preserving its biological activity
Fewer steps in the process to produce casein-free protein mixture
Leaves high concentrations of protein in the remaining crystal-clear whey fraction
Can be easily scaled to large pharmaceutical operations


Zusammenarbeit auf dem CAP-Gebiet mit:

US Army

US Navy

Corixa (NasdaqNM:CRXA)

National Institute Of Health (NIH) (small businness grant)

... weitere bisher nicht öffentlich benannte Partner.




Standbein Nummer 2
Präparate im Bereich Hormontherapie


Hormone Therapy

BioSante is focused on developing a product pipeline of human hormone therapy products. Symptoms treated with hormone therapy in men include impotence, lack of sex drive, muscle weakness and osteoporosis, and in women, menopausal symptoms such as hot flashes, vaginal atrophy, decreased libido and osteoporosis. The market for hormone therapy products (testosterone, estrogen and progestogen products) is approximately $2.5 billion dollars in the U.S. alone.

BioSante’s hormone therapy products are gel formulations of testosterone, estradiol, and combinations of estradiol and testosterone and estradiol and progestogen, respectively. The gels are designed to be quickly absorbed through the skin after application on the arms, shoulders, abdomen or thighs, delivering the required hormone to the bloodstream evenly and in a non-invasive, painless manner.

Current methods for hormone delivery include injections, dermal (skin) patches and a gel for testosterone delivery and oral pills or tablets or dermal patches for estrogen delivery. Dermal patches were developed primarily to promote the therapeutic effects of testosterone therapy without the often painful side effects associated with testosterone injections. Dermal patches, however, have been associated with skin irritation. BioSante’s hormone therapy products are gels formulated to be applied once per day and to be absorbed into the skin without a trace of residue. The testosterone and estradiol products deliver bioidentical hormones similar to men’s and women’s natural hormones.

Hormone Therapy Gel Products:

Bio-T-Gel ™ (male testosterone gel)
Bio-E-Gel ™ (estradiol gel)
LibiGel ™ (female testosterone gel)
LibiGel-E/T™ (estradiol + testosterone gel)
Bio-E+P-Gel™ (estradiol + progestin gel)


BioSante is developing a robust portfolio of transdermal gel hormone therapy products to treat men and women.

BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants, drug delivery systems and biomanufacturing.





Kooperationen (wie oben in dem ProductPipeline-Schaubild abzulesen) mit:

Teva Pharmaceuticals (NasdaqNM:TEVA)

Solvay Pharmaceuticals(London, through SEAQ International (Reuters code SOLtq.LT)




Andere wichtige Fakten:

1. Erstes Gel steht unmittelbar vor Phase III-Tests
FDA-Richtlinie: lediglich 3-monatiger Phase III-Test für
ein Gel dieser Art notwendig !!!!!!!!!!!!!!!!!!!!

2. Vor Kurzem 10,8 Millionen Dollar Investition durch
institutionelle Anleger

3. OTCBB gelistet, völlig unentdecktes Unternehmen und alles
andere als eine der üblichen OTC-Klitschen. Nasdaq- bzw.
Amexlisting in 2004 !(?)

Ticker: BISP
Kurs: 3$
Marketcap: ca. 40 Millionen Dollar
Website: http://www.biosantepharma.com


Noch ist die Aktie nicht im geringsten gelaufen.....

[luto9]

Kein Handel in Deutschland? Keine WKN?

Wie Kaufen?

[Neoe]

Deutsche WKN:905841

Entgegen meiner letzten Aktienvorstellung ganz einfach zu bekommen. Fast jeder Online-Broker bietet heute die Möglichkeit relativ günstig in den USA zu ordern.

[luto9]

Danke

[isonics]

Gute Arbeit, Neoe. Weiter so!

Isonics

[Araberfan]

Hallo Neoe
Danke für den Tip
Werde die Aktie auf meine Watchlist setzen

Gruss Araberfan

[Araberfan]

Hallo Neoe
Danke für den Tip
Werde die Aktie auf meine Watchlist setzen

Gruss Araberfan

[Falke28]

@ Neoe

Ein wirklich sehr interessantes Unternehmen das Du da vorstellst. Aber warum schüttelst Du den Kopf bei Flamel?

Die Technologie scheint sich schon so gut wie durchgesetzt zu haben. Aus zwei Kooperationen stehen ca. 200 Mio. $ in Aussicht - die Flamel kostet ja gerade mal ca 500 Mio. $.

Ich denke, die haben noch mind. ein Verdopplungspotenzial in diesem Jahr.

Zu Biosante: hier stehen wir auch vor erheblichen Risiken. Fast kein Cash mehr und es mussten schon neue Aktien ausgegeben werden um die weitere Entwicklung der Hormongele voran zu treiben. Aber trotzdem äußerst interessant.
Nur der Vergleich mit Flamel hinkt extrem denke ich...

Gruß
Falke28

[Falke28]

@neoe

Leider gibt es noch mehr Nachteile: die Technologie ist in Linenz von Antares Pharma. Kommt es zur Marktreife, werden die sich eine Scheibe vom Kuchen abschneiden.

Ein weiteres Problem ist, dass die Hormongele nicht langfristig angewendet werden sollten. Sie sind nur für den kurzfristigen Bereich geeignet.

Dr. Harrison noted that results from the Women`s Health Initiative (WHI) study (June 25, 2003, JAMA and subsequent updates), had led to warnings against the long-term use of estradiol/progestin combination products. The study arm using estradiol alone is continuing but women are being advised to consult their physician about all post-menopausal hormone treatment. However, in the context of appropriate short-term use, as may be advised by a physician, Bio-E-Gel could offer an additional treatment option and a significant market opportunity. Antares Pharma will receive milestone payments and royalties on end sales from its arrangement with BioSante. The US market for single-entity estrogen products is estimated by BioSante to currently be greater than $1.0 billion.


Naja, hört sich ja immer noch gut an - aber auch die Risiken sind nicht zu unterschätzen. Sehr positiv ist das private Investment von über 10 Mio. $ (August 2003).

Gruß
Falke28

[greenhorn1998]

Hi Neoe!

Wollte mich schon einmal ganz herzlich für diesen Tip bedanken. Bin aber noch nicht wirklich dazu gekommen, mich näher damit auseinanderzusetzen. Klingt aber auch sehr interessant.

Gruß, greenhorn

[Neoe]

Falke:

Wir sind hier im Nanoboard, daher solltest du dich auf den Nanopart von BioSante konzentrieren. Die Hormongelreihe wird aber definitiv zukünftige Entwicklungen finanzieren und wird mit den 10,8 Millionen locker finanziert.

Wir sprechen ja außerdem von mehreren Gels?/Gelen? (doofer Plural,sorry). Und Solvay bzw.Teva wissen unter Garantie, was sie sich angeln. Zu Antares: Sie sind eben auch im Boot, was soll`s.

Verwässerung hat mit der letzten Kapitalerhöhung meiner Meinung nach das letzte, aber objektiv gesehen zumindest das vorletzte Stadium erreicht.

Zu Flamel:
Für mich zu teuer und daher langfristig gesehen nicht lukrativ. Das wäre nur der Fall, wenn ich die Kohle hätte, tausende von Euro reinzpumpen....für mich ein Kriterium;ich brauche die Aussicht, damit reich werden zu können. Warum sollte ich sonst wetten?

[Falke28]

@ Neoe

Du scheinst wirklich die falsche Einstellung zu haben mit Deiner Meinung zu Flamel.

Wo bitte schön ist denn eine Biosante "billig" während eine Flamel "teuer" ist?

Wenn Du mich so nett darauf hinweist, dass ich doch den "Nano-Aspekt" dieser Aktie hier herausstellen soll, dann schau doch mal lieber erst auf die Finanzierung des ganzen Quatsches. Bisher wurden nun mal nur die Hormongele finanziert. Ohne die scheint der gesamte Saftladen ja nix zu bringen!!! Und selbst hier war eine Menge Geld von "außen" nötig.

Gruß
Falke28
Falke28

[Neoe]

Falke:

Willst du jetzt mich oder die Leute hier im Board verarschen ?

Wenn du naiv genug warst über 30$ noch bei Flamel zu investieren dann viel Glück. Ich spezialisiere mich persönlich auf Microcaps und zu dieser Riege gehört Flamel schon lange nicht mehr an.

Flamel hatte ich bei ca. 2,5 Dollar im Auge und habe damals leider nicht zugeschlagen. Heute sehe ich hier keine Luft nach oben mehr, ausser es kommt zu idiotischen Übertreibungen.


Zum Thema Finanzierung der CAP-Technologie:

Die Testergebnisse waren bisher durchgehend gut, man hat NIH-Unterstützung bekommen, wenn auch nur 100,000$. Mehr ist in der ersten Phase nicht drin. In der zweiten sind bereits Millionenbeträge möglich und die Wahrscheinlichkeit, dass es zu der kommt ist gross, wenn man bereits die US Navy und die US Army am Haken hat. Wo steht hier Flamel ???

Zudem wird früher oder später, ich hoffe noch dieses Jahr, was von Corixa zu hören sein. Und weitere Partner stehen in den Startlöchern.

Und wenn du es nicht verstanden hast: Ich habe gesagt die Hormongelprodukte werden zukünftig (LOCKER) die CAP-Technologie finanzieren. Und die Hormongelprodukte werden wiederum (mindestens zum grössten Teil) von den 10,8 Millionen finanziert, wie schon mal von mir gesagt.

Also lieber Falke, wenn ich mich entscheiden muss zwischen der Fachkenntnis der US Army, der US Navy und der NIH oder Deiner, entscheide ich mich doch lieber für die drei Erstgenannten.

Das keine Missverständnisse aufkommen: BISP ist kein risikoloses Investment, aber für einen OTC-Wert bietet BioSante Fundamentaldaten und wohlgemerkt berechtigte Fantasie, die so selten zu sehen sind.

Wer es ignorieren möchte: bitte schön, aber bitte keine Endlosdiskussion daraus machen.

[Falke28]

@ Neoe

1. Deine Postings habe ich sogar alle durchweg verstanden! Stell Dir vor...

2. Deine unterschwelligen bzw. offensichtlichen arroganten Kommantare kannst Du Dir sparen (Verarschen, naiv etc.). Ich glaube kaum, dass die hier was zu suchen haben. Du scheinst mit konstruktiver Kritik ja nicht viel anfangen zu können - bisschen sensibel was? Ohhhh - tut mir leid.

3. Meine Kompetenzen mit denen der Army zu vergleichen ist wohl der größte Mist den ich je gesehen bzw. gehört habe.

4. Konzentriere Dich auf Deine Microcaps so lange Du willst - ich investiere lieber in gute Aktien!

6. Verstanden hast Du mit Deiner Sensibilität schon gar nichts: ich wollte von Dir wissen, warum Du eine Flamel als "teuer" ansiehst (schau Dir die Zahlungen und die Kooperationen an) - meine "Naivität" geht Dich schon mal gar nichts an - Du scheinst eher ärgerlich über Dich selbst zu sein, da Du eine Flamel eben nicht gekauft hast. Jetzt scheinst Du die gleiche Performance zwingend mit einem anderen Wert nachholen zu wollen um wieder selbst an Deine Kompetenz glauben zu können.

Fazit: Halte Dich an die Fakten und verteidige hier nicht Deine Aktien in die Du Dich offensichtlich verliebt hast.
Eine trockene Diskussion reicht völlig aus - da musst Du ganz ehrlich nicht emotional werden!

Falke28

[Neoe]

Falke:

Du machst was du willst, ich was ich will. Um Flamel mache ich zu diesen Kursen einen so großen Bogen, dass ich kaum noch die Kurve kriegen werde.

Zur Lösung unseres Problems und in der Hoffnung, dass dieser Thread nicht weiter zugemüllt wird solltest du vielleicht einen Thread mit großen, dicken Lettern aufmachen:

FLAMEL BESSER ALS BIOSANTE und dort weiter posten.


Eigentlich habe ich das OTC-Board extra vermieden, um solche Postingorgien nicht aufkommen zu lassen und da hängt man doch schon wieder mitten drin.





Nochmal was mit Substanz mit der du dich leider nicht beschäftigst, sonst wärst du vielleicht im Zusammenhang mit meinem letzten Posting auf folgendes gekommen(Achtung,Arroganz):

Die Verbindung BioSantes` mit staatlichen Institutionen der USA ist von entscheidendem Vorteil, da die USA gerade erheblich in diese Technologie investiert.

Flamel wird von amerikanischer Seite nicht den kleinsten Penny an Förderung und schon gar keinen Auftrag sehen, da sie, jawohl du ahnst es vielleicht, aus Frankreich kommen und dieses Land hat derzeit äusserst schlechte Beziehungen zu den USA.

Förderprogramme der EU sind dagegen weit schwerfälliger, mit jede Menge schleppender Bürokratie verbunden und ein Haufen Länder streiten um wenig Geld. Zudem hat die EU eine weit weniger offentsichtliche Strategie, was sie mit ihren Investitionen letztendlich bezwecken will. In den USA ist dagegen klar, dass jeder Bereich gute Chancen hat, wenn er sich irgendwie vor den Karren der "Homeland Security" spannen lässt.

Die Synthese davon:
Das spricht nicht unbedingt gegen Flamel, da sie auch ohne Fördergelder längst in einem Stadium sind, um überlebensfähig zu sein.
Dagegen spricht es umso mehr für BioSante, da sie von einem Umfeld gestützt werden, dass nicht nur aus dem privaten Sektor besteht, sondern auch aus dem staatlichen.

Deswegen wage ich die Prognose, dass, wenn heute BioSante der Apfel und Flamel die Birne ist, wir es morgen schon mit zwei Birnen zu tun haben. Und bei BioSante kann ich diese Entwicklung noch komplett mitnehmen.


In diesem Sinne: Herzlichen Dank Falke.

[Chalifmann3]

Falke, eine Flamel ist jetzt "teuer" weil sie gerade mal
18 Mio-$ Umsatz macht gegenüber ihrer Mcap. von 600 Mio-$
d.h. das KUV ist vergleichsweise viel zu hoch bzw. der
Aktienkurs flitzt irgendwo 5-10 Jahre in der Zukunft rum ...

[isonics]

Ich hänge mich ja nur ungern rein, weil hier ja eigentlich Biosante das Thema ist.Aber ihr dürft im Bezug auf Flamel eines nicht vergessen:
Der Laden bekommt 20 Millionen Dollar sofort, 145 Millionen Dollar später und eine zweistellige prozentuale Umsatzbeteiligung an einem Blockbuster-Insulin-Medikament mit mehrere MILLIARDEN Marktvolumen pro Jahr.

Bei diesen Fakten (und das ist nur ein Produkt aus Flamels gefüllter Pipeline) sieht es doch wohl eher so aus, als würde Flamel in Richtung Milliarden-Marketcap marschieren und sich in den nächsten Jahren zum riesen Pharma-Konzern entwickeln.

Nur zur Klarstellung: Ich finde Biosante gut. Aber Flamel beginnt gerade, in einer ganz anderen Liga zu spielen!

Grüße

Isonics

[Neoe]

isonics:

Wie gesagt, Flamel ist ein gutes Unternehmen, das wohl längst über den Berg ist.

Den Vergleich mit BioSante zog ich, weil ich eben darauf hinweisen wollte, dass man hier mit ziemlicher Sicherheit in etwa dieselbe, wenn nicht sogar eine bessere Story erleben kann.

Flamel ist mir nicht zu teuer, weil ich sage, dass ein weiterer Anstieg heute (aus Hype) oder in ein paar Monaten oder Jahren aufgrund der Fundamentaldaten nicht möglich ist. Ich sage lediglich ich investiere in kein Unternehmen dieser größe und schon gar nicht bei dem KUV und KGV. Dies ist meine Investitionsphilosophie und man fährt gut mit ihr, solange man die kleinen Unternehmen,in die man investieren möchte auf Mark und Knochen überprüft.

Soviel zu Flamel und meinen Investitionsideen und kein Wort mehr von mir zu diesem Thema.

[greenhorn1998]

Oui, ganz genau!

Ganz lustig, fand auch eure Diskussion der letzten Tage noch nicht einaml unsachlich. Weiß auch nicht, wer, was,wann und warum in den falschen Hals gekriegt hat. Konzentrieren wir uns lieber wieder auf die Unternehmen.

In diesem Sinne eine gute Nacht!

Gruß, greenhorn

[Falke28]

@ isionics

Ich bin ganz Deiner Meinung!

@ Neoe

Sagen wir doch einfach, dass Biosante ohne Frage ein interessantes Unternehmen ist - genauso wie Flamel.

Mich störte nur Dein Vergleich ganz erheblich - diese Unternehmen sind meiner Meinung nach nicht zu vergleichen (siehe isionics). Auch Deine Philosophie bezogen auf das KGV und KUV ist aus meiner Sicht sehr merkwürdig. Sieht es bei Biosante in dieser Hinsicht denn besser aus?
Naja, die Börse bietet halt viele Möglichkeiten zum Geld verdienen. Hoffe das Deine aufgeht.

Übrigens: wenn Du einen so fundamentalen Fokus hast, dann schau Dir mal die "Natural Health Trends Corp." an. Ist ein "Konkurrent" von Usana mit Wachstumsraten von 50% und einem KGV von 7 !!! Andere Vor- und Nachteile kannste Du auf der Webseite betrachten: naturalhealthtrendscorp.com.

Also viel Spaß und: war trotzdem ein guter Tip!

Gruß
Falke28

[Neoe]

Falke:

Entscheidender Punkt:Marketcap:ca. 40 Millionen; KGV:nicht vorhanden, da late-stage research company

Danke für den Tip, schau ich mir in den nächsten Tagen an.

[Falke28]

@ Neoe

Tut mir leid Neoe aber ich kann nicht anders: meine "Naivität" ist wirklich zum schreien schlecht.

Nehmen wir an, ich hätte Flamel bei 30$ gekauft, dann hätte ich jetzt nur über 30% Gewinn!!! Das ist echt schlecht muß ich sagen; ja, wie "naiv" von mir...


Gruß
Falke28

[greenhorn1998]

Einen wunderschönen guten Tag zusammen!

Hier mal eine kleine Meldung. Nichts weltbewegendes - noch nicht.

BioSante Pharmaceuticals to Present at
UBS Global Life Sciences Conference


LINCOLNSHIRE, Ill. -- Sept. 17, 2003 -- BioSante Pharmaceuticals, Inc. (OTCBB: BISP) announced today that the company is scheduled to present at the UBS Global Life Sciences Conference in New York City on Tuesday, September 23, 2003, at 3:00 PM E.T. Stephen M. Simes, president & CEO of BioSante will give the presentation.

The audio portion of the presentation can be accessed via the UBS website www.ibb.ubs.com. Follow the link for the webcast under the Global Life Sciences Conference heading. A replay will begin approximately three hours after the presentation and will be available until October 25, 2003.

About BioSante Pharmaceuticals, Inc.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins, such as insulin. Additional information is available online at www.biosantepharma.com.

Bis neulich und Gruß,

greenhorn

[greenhorn1998]

Hallo zusammen!

Bin gerade dabei, mich ein bisschen mit Biosante auseinanderzusetzen und stelle hier noch ein bisschen was rein. Hat zwar Neoe größtenteils schon kundgetan, aber besser zu viel als zu wenig, denke ich mir mal.

Corporate Overview
BioSante is an emerging pharmaceutical company developing a robust product pipeline of hormone therapy products to treat both men and women.
BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems.

Mission
Our mission is to develop and commercialize a robust pipeline of novel pharmaceutical products to deliver solid shareholder value.

Strategy
BioSante is pursuing this mission through the following strategies:
Accelerate the development of BioSante`s hormone therapy products
Continue development and partnering of nanoparticulate-based platform technology
In-license additional products that add value to the product portfolio
Implement business collaborations with other pharmaceutical/biotechnology companies

Hier auch noch einmal etwas ausführlicher die Kooperationen und Partnerschaften von Biosante. Ebenfalls schon bekannt, zwecks Übersicht vielleicht:


Partnerships and Licensing

Hormone Therapy Products

BioSante’s territory for these products includes: USA, Canada, Mexico, New Zealand, Malaysia, Australia, Indonesia, Israel, China, South Africa. Countries differ by product.
BioSante to sub-license countries other than USA.

Collaborations signed to date:
BioSante has signed a development and license agreement with Teva Pharmaceuticals USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), under which Teva USA and BioSante will collaborate on the development of a hormone therapy product for the U.S. market. BioSante received an upfront payment of $1.5 million from Teva. In addition, Teva will pay BioSante milestone payments plus royalties on sales of the product commercialized in this collaboration. Teva also will be responsible for continued development, regulatory filings and all manufacturing and marketing associated with the product

Solvay Pharmaceuticals, B.V. sub-licensed BioSante`s estrogen/
progestogen combination transdermal hormone therapy gel product for an initial payment of $2.5 million, future milestone payments and escalating sales-based royalties. Solvay Pharmaceuticals is responsible for all costs of development and marketing for the product. BioSante retains certain co-promotion rights and, in addition to royalties, will be compensated for sales generated over and above those attributable to Solvay Pharmaceuticals` marketing efforts.

Sub-licensed marketing rights to female hormone therapy products in Canada to Paladin Labs Inc. for a US$500,000 investment, future milestone payments and royalties.

CAP

Collaborations signed to date:

Corixa Corporation - licensed calcium phosphate nanoparticulate-based technology (CAP) on non-exclusive basis for use in vaccines against a variety of infectious and autoimmune diseases and cancers. BioSante will receive milestone payments and royalties from any marketed vaccine containing CAP. This license was signed after Corixa completed "partner-funded" feasibility studies using BioSante`s CAP in Corixa vaccine animal models to show safety and efficacy.

U.S. Army - signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army`s Medical Research Institute of Infectious Diseases (USAMRIID) for the development of biodefense vaccines, including anthrax, staph and ricin. The USAMRIID has agreed to grant BioSante an exclusive license to any U.S. patent application or issued patent as a result of the work under the CRADA.

U.S. Navy - signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Navy`s Naval Medical Research Center`s (NMRC) Malaria Program for the development of a malaria vaccine.
In addition, there currently are several additional partner-funded feasibility studies in progress - CAP being tested with several vaccines in development and for drug delivery of proteins.

Partnering/Licensing Opportunities
BioSante currently is looking to broaden the applications of its existing technologies and expand its product portfolio by:

Sub-licensing gel hormone therapy products in all non-U.S. countries
Acquiring additional late-stage development products
Partnering the CAP technology as a vaccine adjuvant and drug delivery platform
Partnering the process for Milk Protein Isolation - Advanced method of selectively isolating biologically active therapeutic proteins from transgenic milk.


Einen ganz spannenden Überblick gibt auch folgende PDF-Datei, natürlich zu finden - und wahrscheinlich von allen Interessierten bereits gefunden - auf der Homepage:

http://www.biosantepharma.com/pub/factsheet.pdf

Dem entnehme ich - was die Aktie anbetrifft - dass Biosante lediglich einen Börsenwert von knapp über 25 Millionen USD hat. Wenn ich nicht irre, hattest du, Neoe, von 40 Millionen USD gesprochen.

War auch schon "billig", jetzt ist es noch "billiger".

Vor allen Dingen, wenn man bedenkt, dass hier vielleicht eine ganz starke Story noch in den Kinderschuhen steckt.

Kinderschuhe? Nur bedingt. Einige Teile der Produktpipeline sind ja schon eher fortgeschritten

Vielleicht macht es Sinn, vor Dienstag eine kleine Position aufzubauen.

In diesem Sinne, Gruß und ein schönes Wochenende, greenhorn

[Neoe]

Greenhorn:

Freut mich, dass du überzeugt bist von BioSante.

Das Fact Sheet beeinhaltet LEIDER noch nicht die neuen Shares, die an die institutionellen Anleger ausgegeben werden mussten (in Folge der 10,8 Millionen-Finanzierung von kürzlich). Dann dürfte die alte Berechnung wieder hinkommen.

[Neoe]

Noch etwas zu Biosantes` führenden Wissenschaftlern:


Steven J. Bell, Ph.D.
Vice President, Research and Pre-Clinical Development

Steven J. Bell, Ph.D. has served as our Vice President, Research and Pre-Clinical Development since October 2000 and served as a Director of Research and Development of BioSante from July 1997 to October 2000. Prior to joining our company Dr. Bell held various positions with Boehringer Mannheim, Hoffman-LaRoche, The Upjohn Company and Boehringer Ingelheim.



Leah M. Lehman, Ph.D.
Vice President, Clinical Development

Leah M. Lehman, PH.D. has served as our Vice President, Clinical Development since January 2001.
Prior to joining our company, Dr. Lehman was Director of Clinical Research with Scientific Research Development Corp. from April 1995 to December 2000. From 1993 to 1995, Dr. Lehman was a clinical statistician at Abbott Laboratories.

[Neoe]

Und eine weitere Präsentation. Da soll ich Karl-Otto heissen, wenn hier nicht was in den Startlöchern steht:

Press Release Source: BioSante Pharmaceuticals, Inc.


BioSante Pharmaceuticals to Present at Friedland Capital`s Biotech, Medical and Healthcare Conference
Friday September 19, 10:00 am ET


LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Sept. 19, 2003--BioSante Pharmaceuticals, Inc. (OTCBB:BISP - News) announced today that its president and chief executive officer Stephen M. Simes will present at Friedland Capital`s Biotech, Medical and Healthcare Conference featuring companies covered by the research firm, J. M. Dutton & Associates in New York City on September 24 at 9:40 a.m. ET. The audio webcast will be available "live," then archived for 60 days at: www.friedlandcapitalevents.com/duttonwebcast.htm
This Friedland Capital Conference will bring together publicly-traded companies in the pharmaceutical and biotech industries. During his presentation Mr. Simes will present BioSante`s corporate message to key members of the investment community including portfolio managers, analysts, brokers and investment bankers. Investors interested in attending the luncheon should contact Friedland Capital at 303-355-6566 or RSVP online to attend (www.friedlandcapitalevents.com).

Mr. Simes also is scheduled to present at the UBS Global Life Sciences Conference in New York City on Tuesday, September 23, 2003, at 3:00 p.m. ET. The audio portion of that presentation can be accessed via the UBS website www.ibb.ubs.com. Follow the link for the webcast under the Global Life Sciences Conference heading. A replay will begin approximately three hours after the presentation and will be available until October 25.

About BioSante Pharmaceuticals, Inc.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins, such as insulin. Additional information is available online at www.biosantepharma.com.

[greenhorn1998]

Hi Neoe!

Ich hatte gerade auf "Absenden" geklickt, da kam mir just dieser Gedanke, dass die neuen Shares noch nicht berücksichtigt sein könnten. Zu spät eingefallen, Schande über mein Haupt
Werde demnächst besser aufpassen

Wie auch immer, komme wirklich zu der Überzeugung, dass Biosante ein spannendes Unternehmen sein könnte. Danke noch mal für die Informationen, auch die letzten.

Ich nehme an, du bist bereits investiert? Überlege, mir vielleicht am Montag eine kleine, ausbaufähige Position anzueignen.

In diesem Sinne,

Gruß, greenhorn

[Neoe]

greenhorn:

Ich stelle nur Aktien vor in die ich zu diesem Zeitpunkt bereits investiert habe.

Ich gehe fest davon aus, dass du keinen Fehler machst, falls du zuschlagen solltest. Schönen Sonntagabend noch.

[greenhorn1998]

Hi!

Heute und morgen sind für meinen Geschmack ziemlich spannende Tage. Bin sehr neugierig, was Biosante auf den beiden Präsentationen so zu berichten hat. Augen und Ohren offen halten

Gruß, greenhorn

[greenhorn1998]

Hallo zusammen!

Hier der Link, damit ihr euch die Präsentation auf der UBS-Konferenz anhören könnt.

http://event.streamx.us/event/Day.asp?Event=UBS20030922&Even…

Ich hoffe, er funktioniert.

Gruß, greenhorn

[greenhorn1998]

Hallo zusammen!

Ich habe mir die Präsentation einmal angehört. Für meinen Geschmack klang das alles recht vielversprechend. Leider - für meinen Geschmack - wurde der Schwerpunkt vor allen Dingen auf die kurzfristigen Potenziale des Unternehmen gesetzt, also die Hormon-Produkte. Das klang sehr positiv! Simes betonte, dass Biosante sehr große Chancen habe, sich in diesem Markt gut zu positionieren. Dieser sei zwar insgesamt eher klein, aber für Biosante als ein Smallcap-Unternehemn, dass erst am Anfang stehe, wäre es ein großer und wichtiger Erfolg.
Ich fand es nur schade, dass Simes nur sehr wenig über die CAP-Technologie gesprochen hat.

Zum Thema OTC: Er (Simes) wisse, dass es bessere Handelsplätze gebe (Oder gäbe? Wie peinlich. ), aber hat die Hoffnung, vor allen Dingen gestützt durch die erfolgreiche private Platzierung, dass man eher bald als später wechseln könne. Angestrebt wird erst einmal ein Listing an der Amex.

Hoffe ich habe das alles richtig wiedergegeben. Habe die Präsentation nur einmal gehört, kann also sein, dass ich etwas falsch verstanden oder nicht mitbekommen habe. Bitte selbst reinhören!!!

Ich bin gespannt, was heute so passiert!

In diesem Sinne,

Gruß, greenhorn

[Neoe]

Wer sich die seriösen Aussagen von Simes zu gemüte führt, weiss spätestens jetzt, dass wir es hier nicht mit dem üblichen OTC-Hype zu tun haben werden. 100erte von Prozent werden hier nur auf einen Schlag zu verdienen sein, wenn wirklich bahnbrechende News kommen und nicht durch irgendwelchen gepushten Firlefanz, wie sonst an der OTC üblich.

Fazit: BioSante ist ein klares long-term-investment.


greenhorn:
Ich denke es ist in gewisser Weise verständlich, dass vor allem das Kurzfristpotential angesprochen wurde, da Simes wohl auch kurzfristig Kapital anziehen möchte. Dies würde auch zu dem Wunsch passen, die OTC schnell zu verlassen. Dafür müssen wir immerhin kurzfristig über die 4 Dollar gelangen, um die Listing-Regeln zu erfüllen.

[greenhorn1998]

Hi zusammen!

Da kann man nur sagen: Alle Achtung, das ging aber schnell!


BioSante Pharmaceuticals Approved for Listing
on the American Stock Exchange

LINCOLNSHIRE, Ill. -- Sept. 25, 2003 -- BioSante Pharmaceuticals, Inc. (OTCBB: BISP) today announced that its common stock has been approved for listing on the American Stock Exchange® ("Amex®"). BioSante`s common stock is expected to commence trading on the Amex under the symbol "BPA" on October 1, 2003.

"Our listing on the Amex is another significant milestone in the development of our company," said Stephen M. Simes, president and chief executive officer of BioSante. "The listing provides greater visibility for BioSante, and we believe it will expand the base of investors who purchase BioSante stock, providing additional liquidity and value for our stockholders."

September 30, 2003 is the last trading day for BioSante common stock on the Over the Counter Bulletin Board. A listing with Amex means that BioSante is no longer required to comply with certain restrictions inherent in being traded on the OTCBB, including restrictions imposed by certain brokerage houses on the ability of their brokers to solicit orders or recommend the purchase of stocks that trade on the OTCBB.

About BioSante Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc. is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. The company also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins such as insulin. Additional information is available online at www.biosantepharma.com.

About the Amex

The American Stock Exchange is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 123 ETFs. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit www.amex.com.

Gruß, greenhorn

[Neoe]

Da hab ich mich wohl vertan mit den listing-requirements.
Was für ein angenehmer Fehler.

[Neoe]

Achtung, hier passiert was. Riesengap:

Bid 3,33
Ask 5,00

"Nur" der Wechsel an die AMEX oder gleich noch mehr gute News ?

[Neoe]

Damit sind wir die OTCBB los:


BioSante Pharmaceuticals Commences Trading On the American Stock Exchange

LINCOLNSHIRE, Ill., Oct 1, 2003 (BUSINESS WIRE) -- BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that its common stock has begun trading on the American Stock Exchange(R) ("Amex(R)") under the ticker symbol BPA.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante`s hormone therapy products are gel formulations for topical administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis. The estrogen and testosterone markets in the United States alone account for over $2.5 billion in annual sales. BioSante also is developing its calcium phosphate nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems. Additional information on the company is available online at www.biosantepharma.com.

"We are pleased to welcome BioSante to the American Stock Exchange," said John McGonegal, vice president of the Amex Equities Group. "We look forward to working with BioSante on their continued commitment to creating shareholder value by building upon their solid innovation within the biopharmaceutical industry."

"We are delighted with our move to the American Stock Exchange and its considerable support structure," said Stephen M. Simes, president and chief executive officer of BioSante. "We believe our American Stock Exchange listing will result in a broader base of investors and provide additional liquidity and value to BioSante`s stockholders as we continue to develop new products."

BioSante will be represented by the specialist firm of Cohen Specialists LLC on the Amex trading floor.

The Amex is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 123 ETFs. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. For more information, please visit www.amex.com.

[greenhorn1998]

Hallo zusammmen!

Biosante präsentiert sich auf der Rodman & Renshaw Techvest Healthcare Conference vom 21. bis 23. Oktober 2003.

http://www.rodmanandrenshaw.com/rodman.asp?link=uspresenterl…

Schönen Sonntag noch!

greenhorn

[greenhorn1998]

Hallo!

Vielleicht eine etwas doofe Frage und die ganze Geschichte betrifft nur mich, aber ich komme nicht mehr auf die Homepage von Biosante. "Server nichtgefunden" ist das einzige, was ich zu Gesicht bekomme. Hiillllffffeeeee!

Gruß, greenhorn

[Neoe]

greenhorn:

Hab das selbe Problem.

Entweder Serverausfall oder Homepageupdate.

[Neoe]

Kurze Erklärung für loss_pro, falls er sie lesen möchte:

Hier das ursprüngliche Dokument auf das alles zurückgeht (vor dem 1 for 10 reverse split):




Subject to Completion, dated May 3, 2002

The information in this prospectus is not complete and may be changed. We may not sell these securities until the Securities
and Exchange Commission declares our registration statement effective. This prospectus is not an offer to sell these
securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PROSPECTUS

BIOSANTE PHARMACEUTICALS LOGO

25,437,500 Shares

Common Stock
----------------------------------------------------------------------------------------------------------------------------

Selling stockholders of BioSante Pharmaceuticals, Inc. are offering 25,437,500 shares of common stock. BioSante will
not receive any proceeds from the sale of shares offered by the selling stockholders.

The shares of common stock offered will be sold as described under the heading "Plan of Distribution," beginning on
page 21.

Our common stock is quoted on the Over-the-Counter Bulletin Board under the symbol "BTPH." On May 1, 2002, the last
reported sale price of our common stock on the OTC Bulletin Board was $0.52 per share.
----------------------------------------------------------------------------------------------------------------------------

The common stock offered involves a high degree of risk. We refer you to "Risk Factors," beginning on page 6.
----------------------------------------------------------------------------------------------------------------------------

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of
these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal
offense.
----------------------------------------------------------------------------------------------------------------------------

The date of this prospectus is , 2002
----------------------------------------------------------------------------------------------------------------------------

TABLE OF CONTENTS

<TABLE>
Page
SUMMARY 3
RISK FACTORS 6
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS 15
USE OF PROCEEDS 15
DIVIDEND POLICY 16
SELLING STOCKHOLDERS 16
PLAN OF DISTRIBUTION 18
PRICE RANGE OF COMMON STOCK 20
SELECTED CONSOLIDATED FINANCIAL DATA 22
MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 23
BUSINESS 31
MANAGEMENT 46
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 54
SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS AND MANAGEMENT 55
DESCRIPTION OF CAPITAL STOCK 57
LEGAL MATTERS 59
EXPERTS 59
WHERE YOU CAN FIND MORE INFORMATION 60
INDEX TO FINANCIAL STATEMENTS F-1
</TABLE>

----------------------------------------------------------------------------------------------------------------------------

In this prospectus, references to "BioSante," "the company," "we," and "our," unless the context otherwise requires,
refer to BioSante Pharmaceuticals, Inc.

We own or have the rights to use various trademarks, trade names or service marks, including BioSante(TM),
Bio-Vant(TM), NanoVant(TM), CAP-Oral(TM), Bio-Air(TM), Bio-T-Gel(TM), Bio-E-Gel(TM), Bio-E/P-Gel(TM), LibiGel(TM) and
LibiGel-E/T(TM)
----------------------------------------------------------------------------------------------------------------------------

You should rely only on the information contained in this prospectus. We have not authorized any other person to
provide you with different information. This prospectus may only be used where it is legal to sell these securities. The
information in this prospectus is accurate as of the date on the front cover. You should not assume that the information
contained in this prospectus is accurate as of any other date.
----------------------------------------------------------------------------------------------------------------------------



SUMMARY

The items in the following summary are described in more detail later in this prospectus. This summary provides an
overview of selected information and does not contain all the information you should consider. Therefore, you should also
read the more detailed information contained in this prospectus, including the financial statements.

Our Company

We are a development stage biopharmaceutical company that is developing a pipeline of hormone replacement products
to treat hormone deficiencies in men and women. We also are engaged in the development of our proprietary calcium phosphate,
nanoparticulate-based platform technology, or CAP, for vaccine adjuvants, proprietary novel vaccines, drug delivery systems
and to purify the milk of transgenic animals.

To enhance the value of our current pharmaceutical portfolio, we are pursuing the following corporate growth
strategies:

o o
accelerate the development of our hormone replacement products;


o
continue to develop our nanoparticle-based platform technology, or CAP, and seek assistance in such
development through corporate partner sub-licenses;


o
license or otherwise acquire other drugs that will add value to our current product portfolio; and


o
implement business collaborations or joint ventures with other pharmaceutical and biotechnology
companies.

Our primary focus is to build a pipeline of hormone replacement products for the treatment of human hormone
deficiencies. Symptoms of hormone deficiency in men include impotence, lack of sex drive, muscle weakness and osteoporosis,
and in women, menopausal symptoms, such as hot flashes, vaginal atrophy, decreased libido and osteoporosis.

Our proposed hormone replacement products, which we license on an exclusive basis from Antares Pharma Inc., are gel
formulations of testosterone, estradiol, a combination of estradiol and testosterone and a combination of estradiol and a
progestogen. The gels are designed to be absorbed quickly through the skin after application on the arms, shoulders, abdomen
or thighs, delivering the hormone to the bloodstream evenly and in a non-invasive, painless manner. Human clinical trials
have begun on four of our hormone replacement products, a necessary step in the process of obtaining United States Food and
Drug Administration, or FDA, approval to market the products.

The following is a list of our hormone replacement gel products in development:


o o
LibiGel--a transdermal testosterone gel in Phase II clinical development for treatment of female sexual
dysfunction.


o
Bio-T-Gel--a transdermal testosterone gel in development for testosterone deficiency in men.


o
Bio-E-Gel--a transdermal gel containing estradiol in development for estrogen deficiency in women,
including menopausal symptoms.


o
Bio-E/P-Gel--a transdermal gel containing estrogen and progestogen in development for estrogen
deficiency.


o
LibiGel-E/T--a transdermal gel containing estrogen and testosterone in development for treatment of
female sexual dysfunction.

Our CAP technology, which we license on an exclusive basis from the University of California, is based on the use of
extremely small, solid, uniform particles, which we call "nanoparticles," as immune

3
----------------------------------------------------------------------------------------------------------------------------


system boosters, for drug delivery and to purify the milk of transgenic animals. We have identified four potential initial
applications for our CAP technology:

o o
the creation of improved versions of current vaccines by the "adjuvant" activity of our proprietary
nanoparticles that enhance the ability of a vaccine to stimulate an immune response;


o
the development of new, unique vaccines against diseases for which there currently are few or no
effective methods of prevention (e.g., genital herpes);


o
the creation of inhaled and oral forms of drugs that currently must be given by injection (e.g.,
insulin); and


o
the purification of the milk of transgenic animals, in which protein pharmaceuticals are grown by
selectively isolating biologically active therapeutic proteins from the transgenic milk.

The following is a list of our CAP products in development:


o o
Bio-Vant--CAP adjuvant technology--new proprietary CAP technology in development for improved versions
of current vaccines and new vaccines against cancer, viral and bacterial infections and autoimmune diseases.


o
Bio-Air--advanced proprietary technology using CAP as a delivery system for inhalable versions of
therapies that currently must be injected.


o
CAP-Oral--an advanced delivery system using proprietary CAP technology for oral administration of
therapies that currently must be injected.


o
CAP biotechnology production--use of CAP technology in a new patented process for extracting therapeutic
proteins from transgenic milk.

Our company, which was initially formed as a corporation organized under the laws of the Province of Ontario on
August 29, 1996, was continued as a corporation under the laws of the State of Wyoming on December 19, 1996 and was
reincorporated under the laws of the State of Delaware on June 26, 2001.

Our principal executive offices are located at 111 Barclay Boulevard, Suite 280, Lincolnshire, Illinois 60069, and
our telephone number is [phone]. Our web site is located at www.biosantepharma.com. Our web site, and the information
contained on that site, or connected to that site, are not intended to be part of this prospectus.






Hier Teile des Prospekts vom 5.September, der massgebend ist:




PLAN OF DISTRIBUTION

We are registering the shares of common stock on behalf of the selling security holders. Sales of shares MAY be made
by selling security holders, including their respective donees, transferees, pledgees or other successors-in-interest,
directly to purchasers or to or through underwriters, broker-dealers or through agents. Sales may be made from time to time
on the over-the-counter market or otherwise, at market prices prevailing at the time of sale, at prices related to market
prices, or at negotiated or fixed prices. The shares may be sold by one or more of, or a combination of, the following:

o o
a block trade in which the broker-dealer so engaged will attempt to sell the shares as agent but may
position and resell a portion of the block as principal to facilitate the transaction (including crosses in which
the same broker acts as agent for both sides of the transaction);


o
purchases by a broker-dealer as principal and resale by such broker-dealer, including resales for its
account, pursuant to this prospectus;


o
ordinary brokerage transactions and transactions in which the broker solicits purchases;


o
through options, swaps or derivatives;


o
in privately negotiated transactions;


o
in making short sales or in transactions to cover short sales; and


o
put or call option transactions relating to the shares.


The selling security holders may effect these transactions by selling shares directly to purchasers or to or through
broker-dealers, which may act as agents or principals. These broker-dealers may receive compensation in the form of
discounts, concessions or commissions from the selling security holders and/or the purchasers of shares for whom such
broker-dealers may act as agents or to whom they sell as principals, or both (which compensation as to a particular
broker-dealer might be in excess of customary commissions). The selling security holders have advised us that they have not
entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of
their securities.

The selling security holders may enter into hedging transactions with broker-dealers or other financial
institutions. In connection with those transactions, the broker-dealers or other financial institutions may engage in short
sales of the shares or of securities convertible into or exchangeable for the shares in the course of hedging positions they
assume with the selling security holders. The selling security holders may also enter into options or other transactions
with broker-dealers or other financial institutions which require the delivery of shares offered by this prospectus to those
broker-dealers or other financial institutions or loan or pledge shares of common stock to a broker-dealer, who may sell the
loaned shares or, in the event of default, sell the pledged shares. The broker-dealer or other financial institution may
then resell the shares pursuant to this prospectus (as amended or supplemented, if required by applicable law, to reflect
those transactions).

The selling security holders and any broker-dealers that act in connection with the sale of shares may be deemed to
be "underwriters" within the meaning of Section 2(11) of the Securities Act of 1933, and any commissions received by
broker-dealers or any profit on the resale of the shares sold by them while acting as principals may be deemed to be
underwriting discounts or commissions under the Securities Act. The selling security holders may agree to indemnify any
agent, dealer or broker-dealer that participates in transactions involving sales of the shares against liabilities,
including liabilities arising under the Securities Act. We have agreed to indemnify each of the selling security holders and
each selling security holder has agreed, severally and not jointly, to indemnify us against some liabilities in connection
with the offering of the shares, including liabilities arising under the Securities Act.

19
----------------------------------------------------------------------------------------------------------------------------


The selling security holders will be subject to the prospectus delivery requirements of the Securities Act. We have
informed the selling security holders that the anti-manipulative provisions of Regulation M promulgated under the Securities
Exchange Act of 1934 may apply to their sales in the market.

Selling security holders also may resell all or a portion of the shares in open market transactions in reliance upon
Rule 144 under the Securities Act, provided they meet the criteria and conform to the requirements of Rule 144.

Upon being notified by a selling security holder that a material arrangement has been entered into with a
broker-dealer for the sale of shares through a block trade, special offering, exchange distribution or secondary
distribution or a purchase by a broker or dealer, we will file a supplement to this prospectus, if required pursuant to
Rule 424(b) under the Securities Act, disclosing:

o o
the name of each such selling security holder and of the participating broker-dealer(s);


o
the number of shares involved;


o
the initial price at which the shares were sold;


o
the commissions paid or discounts or concessions allowed to the broker-dealer(s), where applicable;


o
that such broker-dealer(s) did not conduct any investigation to verify the information set out or
incorporated by reference in this prospectus; and


o
other facts material to the transactions.

In addition, if required under applicable law or the rules or regulations of the SEC, we will file a supplement to
this prospectus when a selling security holder notifies us that a donee or pledgee intends to sell more than 500 shares of
common stock.

We are paying all expenses and fees customarily paid by an issuer in connection with the registration of the
shares. The selling security holders will bear all brokerage or underwriting discounts or commissions paid to broker-dealers
in connection with the sale of the shares.

20




Also sprechen wir hier von nichts weiter als einer alljährlich wiederkehrenden Registrierung, die nicht unbedingt zum Verkauf führen muss und wenn sie zum Verkauf führt, dann meist nur deswegen weil merkliche Kurssteigerungen stattfinden. Und die sind hier in
nächster Zeit in der tat zu erwarten.

Das einzige was passiert ist: zu den ursprünglichen 2,5 Millionen (nach reverse-split) kommen weitere 5 oder 7,5 Millionen hinzu, dass ist mir nicht ganz klar, die nun verkauft werden dürfen aber nicht zwangsläufig verkauft werden müssen

[cristrader]

http://quickstart.clari.net/qs_se/webnews/wed/cb/Bil-biosant…

Interessanter Artikel zur CAP Technologie!

BioSante Pharmaceuticals Reports Superior Results With CAP Vaccines
Tuesday, 19-Aug-2003 7:20AM PDT Story from BioSante Pharmaceuticals via BizWire
Copyright 2003 by Business Wire (via ClariNet)


BIOWIRE2K
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Aug. 19, 2003--BioSante Pharmaceuticals, Inc. (OTC BB:BISP) announced today results of several studies demonstrating the superiority of its innovative calcium phosphate nanoparticulate (CAP) vaccine adjuvant and delivery system, BioVant(TM), compared to the only approved adjuvant, aluminum salts (alum). The results were presented at the 6th annual Conference on Vaccine Research in Arlington, Va. The company also recently announced a cooperative research and development agreement (CRADA) with the U.S. Army to use the new technology in the development of biodefense vaccines.


--------------------------------------------------------------------------------

NewsVantage – The most cost effective path to dynamic and compelling content for your site!

--------------------------------------------------------------------------------


In the reported studies, BioVant was combined with antigens from the Epstein-Barr virus (EBV), the Herpes Simplex-2 virus (HSV-2) and the Influenza virus (flu), in proprietary vaccine formulations developed by BioSante scientists. The studies, conducted in a series of animal models, were designed to evaluate the immune enhancement effects of BioVant compared to vaccines using alum.

In the study of EBV vaccines, the antibody (IgG) response was significantly higher for the BioVant-EBV vaccine than that of the alum-adjuvant vaccine. Similarly, in mice inoculated with the HSV-2 vaccine, the BioVant-HSV-2 vaccine elicited a substantially greater immune response than the alum-adjuvant vaccine. Both Th1 and Th2 T-cell responses occurred using the BioVant-HSV-2 vaccine, but the bias was towards a Th1 T-cell response. Furthermore, the BioVant-HSV-2 vaccine provided 100 percent protection after challenge with a lethal dose of live virus.

In the study of flu vaccines, the BioVant-flu vaccine induced an antibody response comparable to that of the alum-based vaccine while using only one percent of the amount of antigen contained in the alum-flu vaccine. These findings suggest BioVant is more potent than alum on a weight-for-weight basis, for the elicitation of virus-specific immunity. Similar advantages for BioVant are observed for bacterial vaccines.

"These study results indicate BioVant may be more potent on a weight-for-weight basis and a safer alternative to alum for immune enhancement of vaccine-induced responses," said Stephen M. Simes, president and chief executive officer of BioSante. "Theoretically, the smaller the amount of virus antigen and adjuvant that must be incorporated into a vaccine, the less likely a patient will experience an adverse reaction."

An adjuvant is a substance that, when added to a vaccine, enhances the vaccine`s effect by stimulating an immune system response. Aluminum salt derivatives, such as alum, currently are the only adjuvants approved by the Food and Drug Administration (FDA) for use in the United States. However, alum has been associated with adverse reactions, such as irritation and inflammation of the injection site, and may also result in an allergic reaction.

In contrast, the basis of BioVant is a synthetic analog of calcium phosphate, a naturally occurring compound similar to that found in teeth and bones. In multiple studies, BioVant has been shown not to cause inflammation at the injection site, and no allergic response has been observed.

Another drawback of alum is the type of immune reaction it typically triggers. Alum primarily promotes a particular subset of T-helper cells, known as Th2 cells, which target extracellular bacterial infections but tend not to be optimal to fight viral infections. BioVant, on the other hand, elicits a biased Th1 cell response with concurrent Th2 response, the combination of which activates T lymphocytes that destroy virally infected cells and which promotes antibody immunity. In this way, the two may serve as complements to each other.

"The results of these studies are quite exciting," Simes said. "We believe CAP, in the form of BioVant, has potential to become an adjuvant of choice for the next generation of vaccines, and we look forward to demonstrating that in our work with the U.S. military."

BioSante recently announced it had signed a cooperative research and development agreement (CRADA) with the U.S. Army`s Medical Research Institute of Infectious Diseases for the development of several needle-free biodefense vaccines, including anthrax and ricin. In February the company announced a CRADA with the U.S. Navy to develop a vaccine for malaria.

Simes noted that BioSante and potential commercial vaccine partners are conducting additional pre-clinical studies of BioVant in several potential vaccines, and the company is continuing to pursue licenses with these and other biotechnology and pharmaceutical companies for further development of CAP in all areas. BioSante has licensed its BioVant adjuvant on a nonexclusive basis to Corixa Corporation for use in a variety of vaccines now in development.

About BioSante Pharmaceuticals, Inc.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems including oral administration of proteins, such as insulin. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. An example of a forward-looking statement in this news release is the statement regarding the potential of BioVant to become an adjuvant of choice for the next generation of vaccines. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante`s filings with the Securities and Exchange Commission, including those factors discussed on pages 17 to 23 of BioSante`s Form 10-KSB, which discussion also is incorporated herein by reference.

[cristrader]

Brandaktuell!!!

http://biz.yahoo.com/bw/031007/75586_1.html

BioSante Pharmaceuticals Announces Initiation of Phase III Clinical Trial of Bio-E-Gel
Tuesday October 7, 11:40 am ET


LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Oct. 7, 2003--BioSante Pharmaceuticals, Inc. (Amex:BPA - News) announced today it has initiated a pivotal Phase III clinical trial of Bio-E-Gel(TM) (estradiol topical gel) for the treatment of moderate-to-severe hot flushes and vaginal atrophy in menopausal women.
The Phase III trial will be conducted in the United States and Canada and is a randomized, double-blind, placebo-controlled study of symptomatic menopausal women. This trial follows successful completion of a Phase II/III clinical study and two dose-ranging Phase II clinical trials, which demonstrated that Bio-E-Gel topical gel successfully delivers therapeutic doses of bioidentical estradiol and statistically significantly reduces the frequency and severity of hot flushes.

Current Food and Drug Administration (FDA) requirements for approval of new estradiol products include one 12-week Phase III clinical trial. The clinical endpoints of the required Phase III trial include a significant reduction in the severity and frequency of hot flushes at week 4 and week 12 of treatment as compared to placebo. The Bio-E-Gel Phase III clinical trial will test two doses of Bio-E-Gel to maximize the safety profile by identifying the lowest effective dose.

"We are extremely excited to move into this Phase III study of Bio-E-Gel," said Stephen M. Simes, president and chief executive officer of BioSante. "This is the first Phase III trial to be initiated by BioSante, a very important milestone for the company. We have been committed to moving our pipeline of hormone therapy products through clinical trials, and we now have four hormone therapy products in clinical development."

The objective of the completed Phase II/III clinical trial was to identify an effective dose of Bio-E-Gel to study in Phase III development. The Phase II/III trial demonstrated that Bio-E-Gel effectively reduces the severity and frequency of moderate-to-severe hot flushes in menopausal women, according to FDA guidances for development of estrogen products. Additionally, Bio-E-Gel delivers bioidentical estradiol evenly over time without significant fluctuations in blood levels, such as those typically associated with hormone tablets. Furthermore, even though Bio-E-Gel was applied daily to the same site, minimal skin irritation, a side-effect often associated with patches, was observed. Of the 161 women in the trial, only four women experienced a brief episode of mild skin irritation.

"We observe strong patient interest in participating in our trials, which we believe is a reflection of the need for a more natural estrogen therapy that overcomes many of the undesirable effects of current estrogen therapies," Simes said. "We believe Bio-E-Gel will be well positioned to compete in the estrogen market in the U.S., currently estimated to total approximately $2.5 billion in annual sales."

Bio-E-Gel is a gel formulation of estradiol (the bioidentical human estrogen) designed to be quickly absorbed through the skin after topical application on the arms, shoulders, thighs or abdomen, delivering estradiol to the blood stream evenly over time at minimal dosage and in a non-invasive, painless manner. Estrogen products today are approved for the treatment of menopausal symptoms, including hot flushes and vaginal atrophy. Estrogen products are not approved for and should not be used for the treatment or prevention of heart disease.

BioSante`s hormone therapy portfolio

In addition to Bio-E-Gel, BioSante is developing Bio-T-Gel(TM) bio-identical testosterone gel for treatment of men with testosterone deficiency and LibiGel(TM) bio-identical testosterone gel for treatment of female sexual dysfunction. Symptoms of these hormone deficiencies in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms of female sexual dysfunction include low sexual desire.

Additionally, a combination hormone therapy gel product containing estradiol and progestin is being developed under a license with Solvay Pharmaceuticals, B.V, and an unnamed BioSante hormone therapy product is being developed by Teva Pharmaceuticals USA, Inc. under a license agreement. In both agreements, the respective licensees are responsible for development, regulatory filings, manufacturing and marketing associated with their respective products. Also under both agreements BioSante has received upfront payments and will receive milestone payments and royalties when and if the products are approved and marketed.

The estrogen and testosterone markets in the United States alone account for approximately $3 billion in annual sales.

About BioSante Pharmaceuticals, Inc.

BioSante is an emerging pharmaceutical company developing a pipeline of hormone therapy products to treat both men and women. BioSante also is developing its nanoparticulate-based platform technology (CAP) for novel vaccines, vaccine adjuvants and drug delivery systems. Additional information is available online at www.biosantepharma.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, adverse reports from others about products similar to ours, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante`s filings with the Securities and Exchange Commission, including those factors discussed on pages 17 to 23 of BioSante`s Form 10-KSB, which discussion also is incorporated herein by reference.



--------------------------------------------------------------------------------

[greenhorn1998]

Hallo zusammen!

Gute Neuigkeiten, wie ich finde. Frage mich nur, warum der Kurs nicht darauf reagiert hat.

Naja, ich habe Zeit.

Gruß, greenhorn

[Neoe]

greenhorn:

In spätestens zwölf Wochen geht es ab, wahrscheinlich schon in vier, falls sie die Zwischenergebnisse rausbringen.

An sich hätte ich mir auf diese News auch eine stärkere Reaktion gewünscht, aber das zeigt nur das Biosante auf der Landkarte der Investoren noch nicht angekommen ist, aber das wird sich bald ändern.

[poponase]

Kann mir jemand sagen warum der Kurs schon seit Tagen überhaupt nichts macht?

[cristrader]

Sehr interessanter Research-Bericht!
http://www.jmdutton.com/Research/BISP/Reports/BISP_Report_08…